Malignant peritoneal neoplasm+2
Not yet recruitingStudy on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel
Study on Bevacizumab Dose Equivalence for Patients with Ovarian, Fallopian Tube, or Peritoneal Cancer Using Bevacizumab, Olaparib, Carboplatin, and Paclitaxel
- Disease:Malignant peritoneal neoplasmFallopian tube cancer+1
- Substances:BevacizumabCarboplatin+2
Poland- Participants:18–64 years · 65+ years
- Substances:Bevacizumab
- Sponsor:Agencja Badań Medycznych










